Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

Share Price is delayed by 15 minutes
Get Live Data
1,957.50    33.00 (1.71%)
Bid:
1,961.00
Ask:
1,961.50
Spread: 0.50 (0.025%)
Market Cap: £78.45b
GSK Live PriceLast checked at - London Stock Exchange

Intraday Glaxosmithkline Share Chart

Director/PDMR Shareholding

19 Aug 2025 15:30

RNS Number : 9066V
GSK PLC
19 August 2025
 

GSK plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of notional ADSs within Dr Barron's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$39.3600

3,328.441

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-08-15

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Dr Hal Barron

b)

Position/status

Non-Executive Director

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of ADSs within Dr Barron's GSK 401(k) plan account following the reinvestment of dividends

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$39.3600

84

d)

Aggregated information

 

 

N/A (single transaction)

Aggregated volume Price

e)

Date of the transaction

2025-08-15

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

  

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

James Ford

b)

Position/status

SVP and Group General Counsel, Legal and Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GSK plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

American Depositary Shares ('ADSs')

 

ISIN: US37733W2044

b)

Nature of the transaction

Acquisition of notional ADSs within Mr Ford's GSK Executive Supplemental Savings Plan account following the reinvestment of dividends

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

$39.3600

61.934

d)

Aggregated information

N/A (single transaction)

 

Aggregated volume Price

e)

Date of the transaction

2025-08-15

f)

Place of the transaction

 

New York Stock Exchange (XNYS)

 

 

 

 

 

 

 

 

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHSFESAUEISEIA
Date   Source Headline
19th Nov 20257:15 amRNSTransfer of Treasury Shares
19th Nov 20257:00 amRNSTransaction in Own Shares
18th Nov 20253:30 pmRNSDirector/PDMR Shareholding
18th Nov 20257:00 amRNSTransaction in Own Shares
17th Nov 20257:00 amRNSTransaction in Own Shares
14th Nov 20257:00 amRNSTransaction in Own Shares
13th Nov 20253:30 pmRNSDirector/PDMR Shareholding
13th Nov 20257:00 amRNSTransaction in Own Shares
12th Nov 20253:30 pmRNSBlock listing Interim Review
12th Nov 20257:00 amRNSTransaction in Own Shares
11th Nov 20257:00 amRNSTransaction in Own Shares
10th Nov 20253:00 pmRNSGSK publishes provisional dividend dates
10th Nov 20257:00 amRNSTransaction in Own Shares
7th Nov 20257:00 amRNSTransaction in Own Shares
6th Nov 20257:00 amRNSTransaction in Own Shares
5th Nov 20257:00 amRNSTransaction in Own Shares
4th Nov 20257:00 amRNSTransaction in Own Shares
3rd Nov 20253:00 pmRNSTotal Voting Rights
3rd Nov 20257:00 amRNSTransaction in Own Shares
31st Oct 20257:00 amRNSTransaction in Own Shares
30th Oct 20253:30 pmRNSDirector/PDMR Shareholding
30th Oct 20257:00 amRNSTransaction in Own Shares
29th Oct 20257:05 amRNSTransaction in Own Shares
29th Oct 20257:00 amRNS3rd Quarter Results
28th Oct 20257:00 amRNSTransaction in Own Shares
28th Oct 20257:00 amRNSGSK ADC gets orphan drug designation in the EU
27th Oct 20257:00 amRNSTransaction in Own Shares
24th Oct 20257:00 amRNSBlenrep approved by US FDA in multiple myeloma
24th Oct 20257:00 amRNSTransaction in Own Shares
23rd Oct 20257:00 amRNSTransaction in Own Shares
22nd Oct 20257:05 amRNSPositive data for low carbon version Ventolin MDI
22nd Oct 20257:00 amRNSTransaction in Own Shares
22nd Oct 20257:00 amRNSLatozinemab data read out
21st Oct 20257:05 amRNSPositive CHMP Opinion for GSK on Shingrix PFS
21st Oct 20257:00 amRNSTransaction in Own Shares
21st Oct 20257:00 amRNSGSK share positive Ph3 data on tebipenem HBr
20th Oct 20257:00 amRNSTransaction in Own Shares
17th Oct 20257:00 amRNSTransaction in Own Shares
16th Oct 20253:30 pmRNSDirector/PDMR Shareholding
16th Oct 20257:00 amRNSTransaction in Own Shares
15th Oct 20253:30 pmRNSDirector/PDMR Shareholding
15th Oct 20257:00 amRNSTransaction in Own Shares
14th Oct 20257:00 amRNSGSK receives expanded Shingrix approval in China
14th Oct 20257:00 amRNSTransaction in Own Shares
13th Oct 20253:30 pmRNSDirector/PDMR Shareholding
13th Oct 20257:00 amRNSTransaction in Own Shares
10th Oct 20253:30 pmRNSDirector/PDMR Shareholding
10th Oct 20257:00 amRNSTransaction in Own Shares
9th Oct 20257:00 amRNSTransaction in Own Shares
8th Oct 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.